TPXImpact Holdings, a prominent U.K. digital-transformation services group, has expressed confidence in achieving its full-year targets. The company anticipates reporting substantial revenue growth in the first half of the year, in line with its expectations.
Robust Revenue Growth Projection
For the half-year period ending September 30th, TPXImpact Holdings expects to announce revenues ranging between £41 million and £42 million ($49.8 million-$51 million). This impressive projection signifies a like-for-like growth rate of approximately 20% compared to the first half of fiscal year 2023.
Improved Performance Indicators
Additionally, the company predicts an increase in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin from less than 3% in the previous year to 4%-5% during the specified period.
Strong Business Wins and Favorable Financial Position
TPXImpact Holdings has secured new business wins amounting to GBP105 million, while maintaining a robust pipeline. Furthermore, the company's net debt has reduced to GBP13 million as of September 30th, down from GBP17.9 million at the end of June.
Future Outlook and Targets
Based on the positive results from the first half of the year, TPXImpact Holdings reiterates its fiscal year 2024 targets. The company aims for a like-for-like revenue growth rate of 15%-20% and an adjusted EBITDA margin of 5%-6%. Additionally, it targets a net debt range of GBP11 million-GBP12 million by March 31st.
Interim Results Release
TPXImpact Holdings plans to release its interim results in early December, providing a comprehensive overview of its performance.
Our Latest News
Argonaut Gold Misses Production Target at Magino Mine
Argonaut Gold fell short of production target in 2023 due to delays at Magino mine, but remains optimistic about future prospects.
Eupraxia Pharmaceuticals Advances Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals is advancing its trial for the treatment of eosinophilic esophagitis, with updates on dose escalation and enhanced assessments. The Pha...
Ionis Pharmaceuticals' Drug Candidate Shows Promise in Rare Genetic Disorder
Ionis Pharmaceuticals' olezarsen drug candidate achieves key goals in Phase 3 study for familial chylomicronemia syndrome, with significant triglyceride reducti...